What is BioRelix?
BioRelix operates at the intersection of advanced biotechnology and specialized logistics, providing research-grade peptides with a purity threshold of 98% or higher. The company serves a niche market of researchers requiring high-quality compounds such as Retatrutide, Tirzepatide, and Semaglutide. A core component of the BioRelix value proposition is its sophisticated cold-chain delivery infrastructure, which ensures product integrity from the laboratory to the end-user. By integrating independent testing protocols and flexible payment solutions, the company has carved out a distinct position in the competitive landscape of life science research supplies.
How much funding has BioRelix raised?
BioRelix has raised a total of $35.2M across 6 funding rounds:
Series A
$25.8M
Debt
$2.4M
Private Equity
$3.6M
Multiple Rounds
$3.3M
Series A (2007): $25.8M with participation from CHL Medical Partners, Alexandria Real Estate Equities, Inc., Novartis, Aisling Capital, and New Leaf Venture Partners
Debt (2010): $2.4M, investors not publicly disclosed
Private Equity (2011): $3.6M, investors not publicly disclosed
Unspecified (2012): $500K, investors not publicly disclosed
Debt (2012): $2.6M backed by New Leaf Venture Partners, Novartis, and OpGen
Unspecified (2012): $269K with participation from Connecticut Innovations
Key Investors in BioRelix
Novartis
Novartis is a global pharmaceutical manufacturer headquartered in Switzerland, specializing in developing and producing innovative medications and healthcare solutions across multiple therapeutic areas.
New Leaf Venture Partners
New Venture Partners LLC is a global venture capital firm dedicated to corporate technology spinouts, providing a bridge between R&D labs and traditional venture capital markets.
Aisling Capital
Aisling Capital is a leading investment firm specializing in the development and commercialization of innovative healthcare products, biopharmaceuticals, and medical technologies.
What's next for BioRelix?
With the support of its latest strategic investment, BioRelix is well-positioned to optimize its supply chain and expand its reach within the research community. The company's focus on maintaining strict cold-chain logistics suggests a strategic intent to scale its distribution capabilities while upholding the stringent quality control measures that define its brand. Future growth will likely center on enhancing its product catalog and deepening its integration with global research institutions, leveraging the expertise of its seasoned investor base to navigate the complexities of the pharmaceutical and biotechnology markets.
See full BioRelix company page
